Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Lifeloc Reports Third Quarter 2026 Results
BiotechnologyEarnings

Lifeloc Reports Third Quarter 2026 Results

November 16, 2026 9:14 AM

Lifeloc Technologies, Inc. (OTCID:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2026. Third Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.522 million in the third quarter of 2026, resulting in a quarterly net loss of $(85) thousand, or $(0.03) per diluted share. These results compare to net...

Read more
VinFuture Announces Eight Major Events For VinFuture Sci-Tech Week 2026
BiotechnologyConferences

VinFuture Announces Eight Major Events For VinFuture Sci-Tech Week 2026

November 16, 2026 7:45 AM

The VinFuture Foundation has announced that VinFuture Sci-Tech Week 2026 will feature eight major events from December 2 to 8, 2026. Under the theme "Science Drives - Prosperity Rises," the week will bring together world-leading scientists, experts, and technology business leaders to discuss issues critical to humanity's future, ranging from artificial intelligence (AI) and healthcare to ocean technologies and sustainable development. Under the...

Read more
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
BiotechnologyRegulatory

Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML

November 16, 2026 6:32 AM

Thalia Therapeutics plc (AIM:THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces promising interim data from the Phase I Clinical Trial in acute myeloid leukaemia (AML) in patients treated with miRisten™ (THAT-001). This study is being conducted at City of Hope, one of the largest and most advanced cancer research and treatment...

Read more
Biovica Receives Second Work Order from Leading Global Pharmaceutical Company Under Expanded Master Agreement
BiotechnologyRegulatory

Biovica Receives Second Work Order from Leading Global Pharmaceutical Company Under Expanded Master Agreement

November 16, 2026 5:50 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announces a second work order under its recently expanded Master Services Agreement with one of the world's leading pharmaceutical companies. The order covers a new oncology program and follows the first work order of approximately USD 100, 000, announced on July 20th, 2026. This new work order is valued at...

Read more
Nomination Committee of Alligator Bioscience Proposes New Board and Reduced Fees Ahead of Extraordinary General Meeting on 27 November 2026
BiotechnologyRegulatory

Nomination Committee of Alligator Bioscience Proposes New Board and Reduced Fees Ahead of Extraordinary General Meeting on 27 November 2026

November 13, 2026 10:20 AM

Alligator Bioscience (STO:ATORX) The Nomination Committee of Alligator Bioscience AB (publ) ("Alligator" or the "Company") presents its proposals for items 8-10 on the agenda of the extraordinary general meeting to be held on 27 November 2026. The proposals concern the number of board members, board fees, and the election of the board and its chairman. Background The notice of the extraordinary general meeting, published on 27 October 2026,...

Read more
Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
BiotechnologyEarnings

Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates

November 13, 2026 8:30 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported financial results for the third quarter ended September 30, 2026, and highlighted its proposed share exchange transaction with Santersus AG ("Santersus"), which is expected to establish a Nasdaq-listed, clinical-stage company with a...

Read more
eXoZymes to Host Third Quarter 2026 update Conference Call on Thursday, November 19, 2026
BiotechnologyConference Call

eXoZymes to Host Third Quarter 2026 update Conference Call on Thursday, November 19, 2026

November 13, 2026 7:20 AM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer in AI-enhanced biomanufacturing enabling commercial-scale production of rare natural molecules and novel medicines - announced the plan to host a webinar on Thursday, November 19, 2026, at 5:00 PM Eastern Time to discuss its results for the third quarter 2026. A press release detailing these results will be issued prior to the call. CEO of eXoZymes, Michael Heltzen, will lead the call...

Read more
DIAGENS Leads in Two Major Global AI Benchmarks and Extends Chest and Abdominal CT Analysis to 509 Imaging Targets, Ushering in a New Era for Medical Imaging AI
BiotechnologyCompany Update

DIAGENS Leads in Two Major Global AI Benchmarks and Extends Chest and Abdominal CT Analysis to 509 Imaging Targets, Ushering in a New Era for Medical Imaging AI

November 12, 2026 9:55 AM

DIAGENS (HKEX:2526) today announced benchmark results for iMed-6.0, the latest generation of its iMedImage® medical imaging foundation model, and introduced a CT model designed to analyze 509 diseases and imaging findings. In MedBench's multimodal API evaluation, iMed-6.0 Thoth ranked first and Aegis second overall, and the two models also placed first and second, respectively, in each of the three core categories. Thoth also surpassed the...

Read more
Switch Bioworks and International Scientists Set Direction for Nitrogen Fixation in Nature Biotechnology
BiotechnologyPartnerships

Switch Bioworks and International Scientists Set Direction for Nitrogen Fixation in Nature Biotechnology

November 10, 2026 11:37 AM

Switch Bioworks, a deep-tech company developing genetic control systems for the next era of biomanufacturing, starting with nitrogen biofertilizer, led a commentary published today in Nature Biotechnology that charts a path to accelerate the development and commercialization of biological nitrogen fertilizers. The commentary comes at a pivotal moment, as mounting pressures on food security, climate, and global supply chains converge with...

Read more
China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption
BiotechnologyCompany Update

China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption

November 10, 2026 6:45 AM

For enterprises advancing medical AI commercialisation, hospitals are the ultimate testing ground for real-world validation. Algorithms must target specific clinical pain points, adapt to local imaging datasets, and integrate seamlessly with frontline operational workflows. However, replicating customised development and adaptation work across individual healthcare institutions hinders scalable expansion and drives up costs. Now, a newly...

Read more
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
BiotechnologyCompany Update

Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule

November 10, 2026 6:30 AM

Precigen Inc. (Nasdaq:PGEN) reported sharply improved third-quarter results late last week, driven by continuing rapid uptake of its flagship therapy PAPZIMEOS®, as the company achieved positive cash flow a quarter ahead of schedule and posted its second consecutive profitable period. The company's third-quarter PAPZIMEOS net revenue of $72.9 million was up 37% sequentially, bringing cumulative product revenue since launch to approximately $151...

Read more
Vicore Pharma to Participate in the Jefferies Global Healthcare Conference
BiotechnologyCompany Update

Vicore Pharma to Participate in the Jefferies Global Healthcare Conference

November 10, 2026 2:15 AM

Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the Jefferies Global Healthcare Conference. Location: London, UK Format: Fireside chat and 1×1 meetings Date and time: Thursday, November 19, 2026, 12:00-12:25 PM GMT Participants: Ahmed Mousa, Chief Executive Officer Hans Jeppsson,...

Read more
Pacific Edge Labs Publishes More Than 120 Independent Lab Reports, Each Listed With the Testing Lab's Own ID
BiotechnologyCompany Update

Pacific Edge Labs Publishes More Than 120 Independent Lab Reports, Each Listed With the Testing Lab's Own ID

November 9, 2026 9:00 AM

Pacific Edge Labs, a U.S. supplier of research peptides and laboratory research materials, today announced that its public certificate-of-analysis library now lists more than 120 original reports from two independent laboratories, Freedom Diagnostics and Vanguard Laboratory, including 44 reports from September 2026. Each listing shows the testing laboratory, the lab's own report ID and the report date. Reports from Freedom Diagnostics also open...

Read more
Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
BiotechnologyCompany Update

Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel

November 9, 2026 9:00 AM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that it has entered into a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. ("AMI"), a leading Israeli medical technology distributor, for the commercialization of GelrinC®, Regentis' proprietary implant for the repair of damaged knee cartilage,...

Read more
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
BiotechnologyEarnings

IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update

November 9, 2026 8:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company"), a clinical-stage biotechnology company developing investigational therapies and AI-enabled tools for Alzheimer's disease, today reported financial results and business updates for the third quarter ended September 30, 2026. "CALMA enrolled is complete." said Ram Mukunda, Chief Executive Officer of IGC Pharma. "Once the last participant receives the last dose, we will verify...

Read more
BioInvent to Participate in Upcoming Investor Conferences
BiotechnologyCompany Update

BioInvent to Participate in Upcoming Investor Conferences

November 9, 2026 5:40 AM

BioInvent International AB ("BioInvent") (STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that representatives from the Company management team will participate in the following upcoming investor conferences this November and December 2026: BIO-Europe 2026, Cologne, Germany Format: One-on-one meetings Date: November 9-11 Aktiespararna Digital Life Science night, Lund, Sweden Format: Company...

Read more
OSR Health Exercises $15 Million VXM01 Equity Option, Elects Settlement Through Staged Convertible Notes
BiotechnologyCompany Update

OSR Health Exercises $15 Million VXM01 Equity Option, Elects Settlement Through Staged Convertible Notes

November 6, 2026 10:11 AM

OSR Health, Inc. (OTC PINK:OSRH) ("OSR Health" or the "Company") today announced that it has delivered notice to BCM Europe AG ("BCME") exercising in full its $15 million equity option under the Company's VXM01 global license agreement, and has elected to settle the exercise through convertible notes rather than a cash purchase of common stock. From Put Option to Staged Funding Under the VXM01 global license agreement, as amended in October...

Read more
BioFuse Medical Technologies Appoints John E. Schellhorn as Chairman of the Board of Directors
BiotechnologyCompany Update

BioFuse Medical Technologies Appoints John E. Schellhorn as Chairman of the Board of Directors

November 5, 2026 1:50 PM

BioFuse Medical Technologies, Inc., a medical technology company developing next-generation RF tissue sealing and welding technology, today announced the appointment of John E. Schellhorn as Chairman of its Board of Directors. With more than 40 years of medical device industry leadership, Schellhorn brings extensive experience building, transforming, financing and exiting medical technology companies across the U.S., Europe, Asia Pacific and...

Read more
Colombia's Poultry Industry Is Growing; Layered Biosecurity Can Help Sustain that Growth
BiotechnologyCompany Update

Colombia's Poultry Industry Is Growing; Layered Biosecurity Can Help Sustain that Growth

November 5, 2026 10:45 AM

Synexis®, LLC, the leader in touchless, continuous pathogen control technology, announced a strategic collaboration with Representaciones Guma S.A.S., one of Colombia's most established providers of poultry incubation and production technologies. The collaboration will expand access to Synexis patented DHP® technology across Colombia, adding continuous indoor pathogen control to the technologies Guma provides poultry producers throughout the...

Read more
IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears
BiotechnologyCompany Update

IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears

November 5, 2026 10:18 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI) enabled healthcare technologies, today announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3,095,729, "Method and Composition for Treating CNS Disorders". The patent covers the composition of IGC-AD1, an investigational oral therapy for...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?